Routine smear test in women under 25 would cause more harm than good

November 4, 2013, Cancer Research UK
Routine smear test in women under 25 would cause more harm than good

A Cancer Research UK  study shows that the potential benefits of a national cervical cancer screening programme for women under the age of 25 are outweighed by the harms, according to research presented at the National Cancer Research Institute Cancer Conference in Liverpool today.

The research team revealed that inviting 100,000 women aged 20-24 for a would prevent up to 23 cervical cancers overall. When they excluded very early stage cancers, where the treatment is often the same as for pre-cancers, routine screening prevented between three and nine invasive cancers from developing. But this would also mean an estimated 3,000 young women would be treated unnecessarily.

Screening picks up changes in the cervix which -  in - almost always return to normal without treatment. Screening under 25s means many would be treated unnecessarily for changes which would not have caused any harm if they had been left alone. And treatment brings side effects which, for a minority of women, include a risk of serious bleeding and increasing the chance of premature birth in later pregnancies.

The researchers estimated that to prevent one cancer from developing, the NHS would need to perform between 12,500 and 40,000 additional smear tests on women aged 20-24 and treat between 300 and 900 women in that age group.  

Professor Peter Sasieni, Cancer Research UK's expert at Queen Mary University of London, said: "This research quantifies the risks and potential benefits of providing smear tests routinely in women under the age of 25. It seems clear that the risks outweigh the benefits. Decisions about screening programmes and who to invite should be based on careful analysis and it's important to target screening at the right age group for the best possible outcome.

"Cervical screening is a very effective way of preventing cervical cancer in women over the age of 25. Our study shows that screening younger women leads to unnecessary treatment for many, resulting in serious side effects for some.

"This research makes it clear that the policy change to stop cervical screening in women aged 20-24 in England was well justified from a health perspective and was not a cost-cutting exercise."

In England around 1,900 cases of cervical cancer are diagnosed each year in aged 25-64. Since the cervical screening programme was introduced in 1988, incidence rates in England have dropped by more than 40 per centfrom 4,100 cases in 1988 to 2,300 in 2010.

Dr Julie Sharp, Cancer Research UK's head of health information, said: "Whatever your age and whether or not you've had a smear test, it's important to go to your GP if you notice anything out of the ordinary, like bleeding after the menopause, in between periods or after sex or pain during sex . It probably won't be cancer but it's a good idea to get checked out by your doctor who can arrange any necessary diagnostic tests."

Dr Karen Kennedy, NCRI director, said: "This important research will help inform public health policy to provide the most effective programmes to save lives from ."

Explore further: HPV testing could cut cervical cancers by a third

More information: conference.ncri.org.uk/sunday/ … ncer-problem-solved/

Related Stories

HPV testing could cut cervical cancers by a third

June 14, 2013
(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of cervical cancer ...

Too many Pap tests

July 26, 2013
Most Australian women are currently having more Pap smears than their health requires, according to new research led by a University of New South Wales academic.

Regular smear tests boost chances of cure from 66 percent to 92 percent

March 2, 2012
Women can boost their chances of surviving cervical cancer substantially through regular cervical screening, claims a research paper published today in the British Medical Journal.

"Jade effect" helps save lives as cervical cancer rates rise

August 2, 2012
(Medical Xpress) -- The rate of new cervical cancers diagnosed in the UK increased by 15 per cent in a year, according to figures from Cancer Research UK today.

Cervical cancers rise in young women

November 7, 2011
(Medical Xpress) -- The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according ...

Cervical cancer screening and treatment are neglected in low- and middle-income countries

August 13, 2013
While there have been substantial improvements in mortality rates and an increase in access to reproductive health interventions in low- and middle-income countries (LMICs), the global health community is neglecting prevention, ...

Recommended for you

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

Researchers create novel combination as potential therapy for high-risk neuroblastoma

June 18, 2018
Researchers at VCU Massey Cancer Center in Richmond, Virginia, have identified a promising target to reverse the development of high-risk neuroblastoma and potentially inform the creation of novel combination therapies for ...

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Standard myelofibrosis drug can awaken 'dormant' lymphoma

June 18, 2018
Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life ...

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.